.jpg)
.png)
Features
December 15, 2025
U.S. Food and Drug Administration Approves LIB Therapeutics’ LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
CINCINNATI, Ohio – December 15, 2025 – LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company...
Read More...October 6, 2025
Amgen Makes Repatha® Available Through AmgenNow, A Direct-to-patient Program in the US
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch...
Read More...August 25, 2025
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food...
Read More...June 20, 2025
National Lipid Association Releases New Guidance: “LDL Cholesterol Management Simplified in Adults – Lower for Longer is Better”
The National Lipid Association (NLA) today announced the release of a major new clinical guidance document titled “LDL...
Read More...May 28, 2025
Multidisciplinary Teams in Clinical Lipidology and Cardiometabolic Care: A National Lipid Association Expert Clinical Review
This Expert Clinical Review highlights the importance of a collaborative approach to the management of dyslipidemia and...
Read More...Recommendations and Statements
Jun, 2025
The National Lipid Association (NLA) today announced the release of a major new clinical guidance document titled “LDL...
May, 2025
This Expert Clinical Review highlights the importance of a collaborative approach to the management of dyslipidemia and...
Apr, 2025
Familial Chylomicronemia Syndrome: An Expert Clinical Review from the National Lipid Association
The National Lipid Association (NLA) has released a comprehensive clinical review titled “Familial Chylomicronemia...
Apr, 2025
The risk of atherosclerotic cardiovascular disease increases with advancing age.
Mar, 2025
Extreme hypertriglyceridemia, defined as triglyceride (TG) levels ≥1000 mg/dL, is almost always indicative of...